Skip to content

Is microvascular dysfunction an early phenomenon in the development of skeletal muscle insulin resistance? A dietary intervention study in healthy men

Is microvascular dysfunction an early phenomenon in the development of skeletal muscle insulin resistance? A dietary intervention study in healthy men - DESIRE study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON44864
Enrollment
15
Registered
2014-12-18
Start date
2015-01-29
Completion date
Unknown
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity overweight/fatness

Interventions

The intervention consists of a hypercaloric (60% caloric excess) diet, during a period of approximately 30 days, followed by a hypocaloric phase (1.0 x resting energy expenditure), until subjects re

Sponsors

Vrije Universiteit Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Age 18*30 years 2. Male gender 3. Caucasian 4. BMI 20*25 kg/m2 5. Normal insulin sensitivity 6. Normoglycemia at time of screening 7. Normal diet pattern 8. Stable body weight during 6 months before enrolment in the study (

Exclusion criteria

Exclusion criteria: 1. Presence of any relevant disease 2. Use of any relevant medication 3. First-degree relative with type 2 diabetes 4. Smoking 5. Shift work 6. A history of chronic glucocorticoids use or GC use

Design outcomes

Primary

MeasureTime frame
1. Metabolic insulin sensitivity: rate of disappaerance (Rd) en endogenous glucose production (EGP) 2. Vascular insuline senitivityt: changes in microvascular blood volume (MBV)

Secondary

MeasureTime frame
1. Microvascular vasoreactivity in vitro with and without PVAT (myograph technique) 2. Insulin mediated protein expression and activation in microvessels, adipose and skeletal muscle tissue 3. Gen expression of insulin signaling genes in endothelial cells 4. PVAT morphology/characteristics, including adipocyte size, celltypes and expression of adipokines 5. Plasma insulin, glucose, lipid spectrum, inflammatory parameters 6. Physical activity (by means of accelerometry) 7. Gut microbiota composition (fecal analysis)

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)